A registered study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- RANDOMIZED · PARALLEL · PREVENTION · TRIPLE
- Evidence population
- Human clinical study registration
- Participants
- 164
- Population
- ALL · 60 Years to 79 Years
- Duration
- 2024-07-16 to 2027-04-01
- Intervention
- Chicory inulin; Resistant dextrin; Seaweed polysaccharide; Placebo
- Comparator
- Maltodextrin
- Outcomes measured
- Effect on working memory during n-back task fMRI — Measured at baseline and week 26; Effect on working memory performance during n-back task fMRI — Measured at baseline and week 26; Effect on cognitive functioning as measured by a neuropsychological test battery — Measured at baseline, week 13 and we…; Effect on ADAS-Cog Word Recall cognitive assessment (episodic memory) — Measured at baseline, week 13 and week 26; Effect on ADAS-Cog Word Recognition cognitive assessment (episodic memory) — Measured at baseline, week 13 and week 26; Effect on Digit Symbol Substitution Test cognitive assessment (executive function) — Measured at baseline, week 13 and…; Effect on Digit Span Backward Task cognitive assessment (working memory) — Measured at baseline, week 13 and week 26; Effect on Category Fluency Test cognitive assessment (executive function) — Measured at baseline, week 13 and week 26; Effect on ADAS-Cog Orientation cognitive assessment (episodic memory) — Measured at baseline, week 13 and week 26; Effect on tryptophan metabolites — Measured at baseline and week 26; Effect on amyloid-beta (Aβ) biomarker — Measured at baseline and week 26; Effect on neuroplasticity — Measured at baseline and week 26; Effect on brain regions of interest — Measured at baseline and week 26; Effect on hypothalamic-pituitary adrenal axis — Measured at baseline and week 26; Effect on intestinal barrier integrity — Measured at baseline, week 13 and week 26; Effect on intestinal inflammation — Measured at baseline, week 13 and week 26; Effect on gastrointestinal transit time — Measured at baseline, week 13 and week 26; Effect on gastrointestinal symptoms — Measured at baseline, week 13 and week 26; Effect on self-reported stool consistency — Measured at baseline, week 13 and week 26; Effect on stool consistency — Measured at baseline, week 13 and week 26
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 80% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Probiotics and prebiotics · 80%Title contains controlled topic terminology. Title supplies ageing or longevity context.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.